Q-omics provides the consensus-scored PDGFRB profile across patient tissues and cancer cell-line models. PDGFRB expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PDGFRB is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PDGFRB protein abundance shows 25,860 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where PDGFRB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDGFRB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDGFRB survival associations across molecular data types. PDGFRB RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDGFRB RNA expression–survival associations across cancer types. High PDGFRB expression shows unfavorable associations in KIRP, UVM, BLCA, MESO and LGG, but favorable associations in LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PDGFRB RNA expression.
This table summarizes PDGFRB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDGFRB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDGFRB shows lower tumor expression in KIRP and higher tumor expression in HNSC, KIRC, COAD, STAD and LIHC. The HNSC box plot shows higher PDGFRB RNA expression in tumor versus normal tissue (log2 FC = +3.344, t-test p < 0.001).
This table shows molecular features associated with PDGFRB in patient tissues and cancer cell lines. In patient samples, PDGFRB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PDGFRB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
